2023
Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review
Doernberg S, Arias C, Altman D, Babiker A, Boucher H, Creech C, Cosgrove S, Evans S, Fowler V, Fritz S, Hamasaki T, Kelly B, Leal S, Liu C, Lodise T, Miller L, Munita J, Murray B, Pettigrew M, Ruffin F, Scheetz M, Shopsin B, Tran T, Turner N, Williams D, Zaharoff S, Holland T, Patel R, King H, Kinamon T, Dai W, Geres H, Deckard N, Schuler C, Bunn I, Sharma S, Wickward C, Waller J, Wilson H, Mehigan M, Ghazaryan V, Raterman E, Samuel T, Lee M. Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review. Clinical Infectious Diseases 2023, 77: s295-s304. PMID: 37843115, PMCID: PMC10578051, DOI: 10.1093/cid/ciad565.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupMRSA bloodstream infectionsMethicillin-resistant Staphylococcus aureusBloodstream infectionsClinical trialsPediatric community-acquired pneumoniaInfection researchEnterococcal bloodstream infectionsOptimal vancomycin dosingOptimization of dosingRole of dalbavancinCommunity-acquired pneumoniaShort-course therapyInterventional clinical trialsVancomycin-resistant enterococciVancomycin dosingPositive infectionsNovel agentsLife measuresTreat infectionsClinical practiceNarrative reviewInfectionPositive bacteriaStaphylococcus aureusThe Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group
Harris A, Souli M, Pettigrew M, Group F. The Next Generation: Mentoring and Diversity in the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases 2023, 77: s331-s335. PMID: 37843116, PMCID: PMC10578050, DOI: 10.1093/cid/ciad532.Peer-Reviewed Original Research
2021
Antibacterial Resistance Leadership Group 2.0: Back to Business
Chambers HF, Evans SR, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL, Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler VG. Antibacterial Resistance Leadership Group 2.0: Back to Business. Clinical Infectious Diseases 2021, 73: 730-739. PMID: 33588438, PMCID: PMC8366825, DOI: 10.1093/cid/ciab141.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Bacterial AgentsDrug Resistance, BacterialGram-Negative BacteriaGram-Positive BacteriaLeadership
2015
Innovating in health care management education: development of an accelerated MBA and MPH degree program at Yale.
Pettigrew MM, Forman HP, Pistell AF, Nembhard IM. Innovating in health care management education: development of an accelerated MBA and MPH degree program at Yale. American Journal Of Public Health 2015, 105 Suppl 1: s68-72. PMID: 25706023, PMCID: PMC4339991, DOI: 10.2105/ajph.2014.302252.Peer-Reviewed Original Research
2014
Antibacterial Resistance Leadership Group: Open for Business
Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial Resistance Leadership Group: Open for Business. Clinical Infectious Diseases 2014, 58: 1571-1576. PMID: 24610430, PMCID: PMC4017892, DOI: 10.1093/cid/ciu132.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupAntibacterial resistanceClinical research agendaPublic health threatClinical research opportunitiesInfection preventionClinical studiesAntimicrobial stewardshipClinical research proposalsInfectious diseasesClinical researchHealth threatNational InstituteInfectionMedical practiceHigh priority areasNegative bacteriaPositive bacteriaAllergyDiseasePrevention